SALT
LAKE CITY, May 5, 2023 /PRNewswire/
-- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today it will
release its first quarter 2023 results on Thursday, May 11, 2023, after the market close.
The Company will also host a conference call and webcast on the
same day at 4:30 p.m. ET to discuss
its financial results with analysts and institutional investors.
Management on the call will include Dwight Egan, Chief Executive Officer,
Brian Brown, Chief Financial
Officer, and Andrew Benson, Head of
Investor Relations.
The call and webcast will be available via:
Webcast:
|
ir.codiagnostics.com on
the Events & Webcasts page
|
|
|
Conference
Call:
|
844-481-2661 (domestic)
or 412-317-0652 (international)
|
If you are unable to participate during the live webcast, the
call will be recorded and later made available on the Company's
website.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR Home™ platform and to locate genetic
markers for use in applications other than infectious disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-first-quarter-2023-earnings-release-date-and-webcast-301817203.html
SOURCE Co-Diagnostics